Johnson & Johnson to Acquire Proteologix, Inc.

VION Biosciences Acquires Prolytix

September 8, 2026

Biotechnology

VION Biosciences announced the closing of its acquisition of Prolytix, a provider of regulated bioanalytical and CMC services, research reagents, and custom sample collection products. The deal is intended to strengthen VION’s integrated platform across biopharma services and diagnostic workflow inputs, including regulated large-molecule testing and workflow-critical reagents and IVD materials.

AbbVie Acquires Apogee Therapeutics for $10.9 Billion

June 22, 2026

Biotechnology

AbbVie entered into a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion ($135.11 per share). The deal is intended to deepen AbbVie’s immunology portfolio and expand its clinical presence in respiratory diseases, with Apogee’s lead program zurilokibart (APG777) targeting IL-13 for atopic dermatitis and its pipeline including APG273 for asthma. Closing was expected in Q3 2026, subject to customary regulatory and shareholder approvals; AbbVie later announced completion on Sept. 3, 2026.

10x Genomics Acquires Proteintech Genomics to Expand Proteomics Capabilities

June 10, 2026

Biotechnology

10x Genomics announced it has acquired Proteintech Genomics, a division within Proteintech Group, to expand its proteomics capabilities for single-cell and spatial multiomics workflows on 10x platforms. The deal adds Proteintech Genomics’ Human Discovery Panel technology and supports 10x’s strategy of integrating transcriptomic and proteomic measurements, including capabilities planned for its Atera platform. Financial terms were not disclosed.

Johnson & Johnson Acquires Yellow Jersey Therapeutics from Numab for $1.25B

May 28, 2024

Biotechnology

Johnson & Johnson agreed to acquire Yellow Jersey Therapeutics, a wholly owned spin-off of Numab Therapeutics, for $1.25 billion in cash to obtain global rights to NM26, a Phase‑2‑ready bispecific antibody for atopic dermatitis. The deal was announced May 28, 2024 (Numab/ Novo Holdings) and completed in July 2024; J&J will develop, manufacture and commercialize NM26 globally.

Johnson & Johnson to Acquire Ambrx Biopharma in ~$2 Billion All-Cash Deal

January 8, 2024

Pharmaceuticals

Johnson & Johnson announced it has entered into a definitive agreement to acquire Ambrx Biopharma in an all-cash merger transaction valued at about $2 billion (about $1.9 billion net of estimated cash acquired). The deal is intended to add Ambrx’s proprietary synthetic biology and ADC (antibody-drug conjugate) technology platform and its clinical and preclinical oncology pipeline to J&J’s targeted oncology therapeutics efforts.

Eli Lilly Acquires Protomer Technologies

July 14, 2021

Biotechnology

Eli Lilly and Company announced the acquisition of Protomer Technologies, a private biotechnology company based in Pasadena, California, to enhance Lilly's diabetes pipeline. The deal has potential value of over $1 billion contingent on development and commercial milestones; Lilly previously held a 14% stake and is acquiring the remaining shares to gain Protomer's glucose‑sensing insulin programs and protein‑engineering MEPS platform.